Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 07:00 ET | Source: Trained Therapeutix Discovery, Inc.

Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE)

OSS, The Netherlands, April 14, 2026 (GLOBE NEWSWIRE) -- Trained Therapeutix Discovery, a biotechnology company founded by the Jean Boulle Group and the Heritage Group, today announced that its...
April 13, 2026 07:44 ET | Source: Research and Markets

Zynyz (Incyte: retifanlimab-dlwr) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Zynyz Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
April 13, 2026 07:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment...
April 13, 2026 06:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron and Telix Announce Strategic Radiopharma Collaboration

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model Collaboration combines Regeneron’s leading antibody...
April 13, 2026 06:30 ET | Source: Telix Pharmaceuticals Limited

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix’s expertise in...
April 13, 2026 04:00 ET | Source: Epitopea

Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield

CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies...
April 10, 2026 07:14 ET | Source: Mordor Intelligence

Immunohistochemistry Market Led by Diagnostics Segment with 60%+ Share; Market Projected to Reach USD 4.42 billion by 2031, Mordor Intelligence Reports

Immunohistochemistry demand grows in oncology diagnostics and digital pathology as companies like Thermo Fisher, Roche, Agilent and Merck drive innovation.
April 09, 2026 08:45 ET | Source: International Myeloma Foundation

Over 60 Million Showed They Are #MoreThanMyeloma During 2026 Myeloma Action Month

STUDIO CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- As this year’s Myeloma Action Month came to a close, the International Myeloma Foundation (IMF) was truly grateful for the incredible support...
April 09, 2026 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and...
April 09, 2026 07:00 ET | Source: Oxford BioTherapeutics

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s...